Long-Term Follow-up of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients With Intermediate- or High-Risk DLBCL
5-Year POLARIX Study Follow-up
5-Year POLARIX Study Follow-up
According to a prolonged 5-year follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed durable and significant progression-free survival (PFS) benefit vs R-CHOP among patients with intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL).
These results were presented by Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, New York, at the 66th ASH Annual Meeting in San Diego, California.
“Safety profiles remained similar between arms, and no new safety signals were identified,” Salles and coauthors wrote, “These outcomes confirm Pola-R-CHP as a standard of care for patients with previously untreated intermediate- or high-risk DLBCL.”
Source:
Salles G, Morschhauser F, Sehn LH, et al. Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes. Dec 7-10, 2024; San Diego, CA. Abstract: 469
